Technology ID

A Highly Efficient Differentiation Protocol for Placental Cells Derived from Human Pluripotent Stem Cells for Diagnostic and Therapeutic Applications

Lead Inventor
Havel, William (Cook Medical Technologies LLC)
Newkirk, Jeremy (Cook Medical Technologies LLC)
Hadley, Rita (Cook Medical Technologies LLC)
Zhou, Yun (Cook Medical Technologies LLC)
Research Materials
Development Stages
Pre-clinical (in vivo)
Research Products
Human iPSC Lines
Human Cell Lines
Lead IC

This technology includes in vitro-generated trophectoderm (TE) cells, which are ideal for modeling diseases of the placenta, drug screening, and cell-based therapies. The TE lineage which gives rise to placental cells during early human development. Derivation of definitive placental cells from human pluripotent stem cells in culture remains controversial and so far, placental cells can only be derived directly from primary placental tissue, which largely limits their access and study in the laboratory. This invention describes highly efficient TE differentiation, including cytotrophoblast and syncytiotrophoblast cells, by manipulating specific cell signaling pathways in chemically defined conditions.

Commercial Applications
This invention will significantly improve the use of human astrocytes for basic research, drug discovery, disease modeling, and cell therapy.

Competitive Advantages
This is the most efficient and most reproducible astrocyte differentiation protocol from human pluripotent stem cells.
Licensing Contact:
Shmilovich, Michael